No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Guggenheim Maintains Nautilus Biotechnology(NAUT.US) With Buy Rating, Maintains Target Price $2.5
Nautilus Biotechnology | 10-Q: Q1 2025 Earnings Report
Earnings Call Summary | Nautilus Biotechnology(NAUT.US) Q1 2025 Earnings Conference
Nautilus Biotechnology | 8-K: Nautilus Biotechnology Reports First Quarter 2025 Financial Results
Nautilus Biotechnology Targets Late 2026 Platform Launch Amid Proteoform Assay Advancements
Express News | Nautilus Biotechnology Inc: Qtrly Loss per Share $0.13